- Home
- NBXG vs XNCR Comparison
NBXG vs XNCR Comparison
Compare NBXG & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBXG | XNCR |
|---|---|---|
| Founded | 2021 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | NBXG | XNCR |
|---|---|---|
| Price | $14.15 | $16.79 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $22.44 |
| AVG Volume (30 Days) | 243.7K | ★ 738.7K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 10.25% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $150,132,000.00 |
| Revenue This Year | N/A | $18.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 38.16 |
| 52 Week Low | $9.31 | $6.92 |
| 52 Week High | $12.23 | $26.59 |
Technical Indicators
Market Signals| Indicator | NBXG | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 36.83 | 54.79 |
| Support Level | $14.67 | $16.44 |
| Resistance Level | $14.69 | $17.62 |
| Average True Range (ATR) | 0.22 | 0.93 |
| MACD | -0.02 | -0.16 |
| Stochastic Oscillator | 7.69 | 36.50 |
Price Performance
Historical ComparisonAbout NBXG Neuberger Berman Next Generation Connectivity Fund Inc.
Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income. Under normal market conditions, the Fund will invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. companies, in any market capitalization range, that is relevant to the theme of investing in "NextGen Companies".
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.